News | March 21, 2026
Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The facility features 2,176 high-performance GPUs across the US and Europe
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The protections extend through at least 2035, with the potential for further extensions
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Subscribe To Our Newsletter & Stay Updated
